AvodahMed

The company exists to build the model, and the model is the entire product. AvodahMed is the digital health division of an AI company whose sibling division builds language translation technology, which is an unusually direct explanation for a multilingual capability that most scribes assert without provenance. Veradigm Ambient Scribe carries the same intelligence licensed in; here it belongs to the vendor.

Not documented for the direct product, and the distributor's description cannot stand in for it.

Oversight behavior is described in the distributor's materials for the integrated deployment, where codes arrive as suggestions for provider review. An integration partner's description is not evidence about the builder's own product, and on privacy architecture a distributor's characterization and the builder's own documentation do not align. That is a concrete reason for caution rather than a procedural one.

For the direct product nothing is published: no review gate description, no confidence threshold, no acceptance or edit rate, no statement of behavior on uncertain output, and no description of what is flagged for closer attention.

The question has become more consequential since, because of where this output now goes. The vendor has partnered with an autonomous coding provider positioned downstream of its documentation. Where a scribe's output feeds a process explicitly described as autonomous, the oversight model of the scribe itself carries more weight, since it may be the last point at which a person is positioned to intervene before a claim is produced.

No accuracy figure, no model card, no named models, no evaluation methodology. Specialty aware documentation is claimed but neither enumerated nor substantiated. The disclosure runs backward: more is publicly documented about how this model performs by its distribution partner than by the company that built it.

Nothing published by this company identifies any party in its chain: no foundation model provider, model class or version, no hosting arrangement and no subprocessor list, and the parent company's estate does not add one.

The disclosure asymmetry is the distinctive feature, because this engine reaches most of its users through a record system distributor rather than directly. More is publicly documented about how this model behaves by the company that resells it than by the company that builds it.

The audio question is resolved on the builder's own document. The distributor describes the integrated product as producing real time transcripts without generating audio recordings. The builder's provider terms of use state that by using the platform the provider expressly authorizes Avodah to record the verbal exchange between the user or patient and the provider, and to analyze voice and other biometric information in order to provide the services. Recording is therefore authorized in the contract that governs direct use, and the builder's own release documentation describing support for longer audio recordings is consistent with that.

Two consequences follow. The distributor's no recording description is a claim about a deployment configuration rather than about the engine, and a privacy architecture claim made by a distributor about a product it did not build describes a deployment until the builder confirms it. And the biometric clause is a disclosure in its own right. Voice is being analyzed as biometric information, not merely transcribed, and the terms also permit deidentification and use of private information in any manner permitted by law.

Better than pure self report, still short of evidence. The most useful figure is partner reported rather than vendor reported: Veradigm's vice president of technology stated that structured pilots run in September and October 2024 saved an average of seven to ten minutes per encounter, which is a specific operational number from the party doing the integrating.

Against that, AvodahMed's own site carries a customer claim of chart closure rates up by nearly 70 percent with no denominator, and one testimonial appears under both brands with only the product name changed, the same six months of consistent use quote running as AvodahMed on one site and as Veradigm Ambient Scribe in partner coverage. Recycled attribution is not evidence of anything except shared marketing. No study, no controlled comparison, no independent evaluation.

A privacy claim in the distributor's materials does not carry over to this vendor, and the vendor's own documentation shows why.

The distributor described the integrated product as producing real time transcripts without generating audio recordings, which would be a materially better privacy architecture. This vendor's own release documentation describes work to support longer audio recordings, and its own testing guidance instructs users to verify audio alongside transcription and workflows. Those two accounts do not sit comfortably together.

The reconciliation may be innocent. The distributor may be describing a configuration specific to its own deployment, where audio is discarded at the point of transcription. But the engine as documented by the company that builds it handles audio recordings, so the no recording characterization is not shown to apply to a purchase outside that one integration. Even inside it, the material does not state which layer implements it.

That is the substantive lesson and it generalizes: a privacy architecture claim made by a distributor about a product it did not build is a claim about a deployment, not about an engine, until the builder confirms it.

The remaining questions are unanswered. Whether audio is created, where it is held and for how long, whether transcripts persist separately, and whether customer content is used to train or improve models. This vendor's own material answers none of them.

Describes itself directly as a HIPAA compliant ambient scribe on its own materials, and the provider terms state that the platform is designed to comply with HIPAA and applicable privacy laws.

The parent company's security page adds the key element: a business associate agreement is provided on request for customers processing protected health information. That is an explicit posture rather than an inference.

No agreement text, scope statement or execution path is published for inspection before contracting.

The security page belongs to the parent company and its wording covers the parent's conversational AI, and nothing on it says whether the statement is scoped to the medical scribe rather than to the translation division. And the terms allocate patient notification to the customer: the provider is responsible for notifying patients of use of the platform during encounters, and separately for obtaining any required patient consents.

The notification point is sharper than it looks. The same terms authorize recording of the verbal exchange and analysis of voice as biometric information. So what a patient is told, and what they are consenting to, is a question the vendor has placed entirely on the customer, about processing the customer may not know is happening.

Neither type of SOC 2 report is published, and there is no HITRUST certification, no ISO 27001 and no trust center. Health privacy compliance is asserted, which is a self description rather than an examination, and there is no certification for that rule in any case.

Two routes a buyer might mistake for assurance should be named, because both are available here and neither is one.

The first is the marketplace. This vendor's product is listed in a major electronic record supplier's application catalog, which reads as vetting. That catalog's own notice states that listed applications have either self reported production readiness or, where indicated, been tested through a certification process. Two different things in one list, and the catalog says so.

The second is the brand. The scribe is sold under an established record system vendor's name, and a buyer may reasonably assume the larger organization's security posture extends to it. It does not follow. Whatever attestations the distributor holds cover the distributor's own systems, and the encounters are processed by this company.

The absence matters in proportion to position. This vendor sits mid chain, receiving encounter content from a distribution partner and, under a further announced partnership, passing documentation output to an autonomous coding provider. An organization in that position is exactly where a buyer most needs an independent examination, because it is furthest from the buyer's own contract and closest to the data.

No clearance claimed and none required for ambient documentation.

A published position sits in the provider terms of use, which are on the parent domain at avodah.com rather than under the product name. The terms state that the Platform is provided for information and education purposes only and is not designed, intended, made available or authorized by any regulatory body as a medical device, for the diagnosis of disease or other conditions, or as a substitute for professional medical advice, diagnosis, treatment or judgment. A separate clause states that the Platform is a technology platform and does not provide any clinical decision support. That is an express regulatory statement rather than a medical advice disclaimer.

The evidence is the vendor's own terms and its own partnership announcement. The policy analysis referenced below is context rather than the basis, it was not named, and a source that cannot be identified should not be carrying an attribution.

The stated position and the product do not sit comfortably together. Describing a clinical documentation platform whose output is billed from as being for information and education purposes only, and as providing no clinical decision support, is a broader disclaimer than the product supports. The scope question sharpens it. This vendor has announced a collaboration placing an autonomous medical coding provider downstream of its documentation output. Elsewhere the coding boundary usually involves suggestions, which presume a human selects among them; autonomy presumes one does not. A documentation engine feeding a coding system with no human in the selection path produces a claim built from a conversation, and the clinician's signature sits on the note rather than on the code. The coding is the partner's product, and this scribe's output is designed to flow into it.

Commercial framing points the same way, with customer material citing a near 70 percent increase in chart closure rates as enabling more rapid reimbursement.

The organization has published nothing on how its documentation performs across languages and accents. There is no fairness statement, no subgroup analysis, no accuracy breakdown by accent, dialect or speaker population, and no evaluation methodology.

The absence was already noted as more striking here than elsewhere because the parent company's other division builds language technology. That point is sharper than it first appears, because the sibling division is not a peripheral line of business and its claims are clinical.

That division markets clinical language services across more than sixty languages, describing the purpose as clinically safe communication. So one part of the organization makes an explicit clinical safety claim about handling many languages, while the part generating clinical documentation says nothing about how its own performance varies across accents, dialects or language backgrounds.

That combination cuts against the vendor rather than for it. The common defense of silence on fairness is that measuring performance across speaker populations is difficult and beyond a small company's reach. An organization operating a clinical language division across sixty languages cannot make that argument. It holds the linguistic expertise, the evaluation problem is already familiar to it, and the two divisions share a parent and a stated mission about being understood.

The documentation product also serves an integration to which multilingual support has since been added, so the exposure is live rather than theoretical.

This remains the single most valuable disclosure this organization could publish.

Provider terms of use dated May 2026 are published on the parent domain, avodah.com, and they address liability directly.

The terms state a review gate in the contract rather than leaving it implied by the workflow: the provider is told not to rely on the factual accuracy of output from the platform's algorithms, and the accuracy and relevance of any output is subject to review and approval by the provider, who remains responsible for all clinical and treatment decisions. Combined with the express limitation that the platform is for information and education purposes only, something is published about the system being wrong.

Nothing stands behind the output, and the terms are blunt about it. Everything is provided as is, with no representation as to accuracy, completeness, correctness, suitability or validity, and no liability for errors or omissions. In the event of any problem with the platform the stated sole remedy is to cease using it. Aggregate liability is capped at fees paid in the preceding twelve months. Indemnification runs one way, from the provider to Avodah. No accuracy or error figure, no method and no remediation obligation is published. Governing law is Texas.

The operative clause carries a drafting defect. The limitation of liability twice excludes liability for the customer's receipt of ABA therapy services from any provider. Applied behavior analysis therapy is not what this product does, and the reference appears to be transplanted from another agreement. A liability cap that describes the wrong service is a live problem in the document that matters most here.

The terms also leave the distribution route open. This engine reaches most of its users through a record system distributor. The health system contracts with the distributor, which does not control model behavior; this company controls model behavior and has no relationship with the health system. These terms bind a provider who buys direct. They do not reach a clinician using the product embedded in a partner's record system, and no document covering that combined product is published. Nothing published says which entity carries the performance representations in a purchase through the distributor, or whether any supplier warranty passes through the reseller.

Two documented routes with real depth rather than a long list of shallow ones. It is listed on the athenahealth Marketplace, and it holds the deepest possible position inside Veradigm, which selected it specifically for integration depth over lightly integrated alternatives and certified it through the Veradigm Connect program. That is a meaningful third party judgment about integration quality, made by a party with its own EHR to protect.

No hosting region, residency option or subprocessor list is published.

The shape of the chain matters more than the missing detail, because this vendor sits in the middle of one and most customers will never see the whole of it.

At one end a practice contracts with its electronic record supplier and buys an ambient scribe carrying that supplier's brand. This company builds and operates that scribe, so it is already a party the practice has probably not contracted with directly. This company has in turn announced a partnership placing an autonomous coding provider downstream of its documentation output. That is at least three organizations touching one encounter, and the practice's paperwork reaches the first of them.

The product is also sold directly, not only through that integration, so the chain differs by purchase route. A direct buyer has a shorter chain and a different set of terms from a buyer acquiring the same engine under another company's brand, and neither can infer their position from the other's.

None of the ordinary questions is answered anywhere: where processing runs, whether a third party model service is involved, what is retained and for how long, or which entity holds what. Nothing published names the organizations that process or receive encounter content, the order they do it in, the terms between them, or what changes if the distribution or coding partnerships end.

No rate card is published for the direct product. Pricing runs through a demo request, and the embedded route is priced inside a Veradigm EHR contract, so neither path exposes a comparable number.

Ambulatory, with specialty aware documentation claimed but no specialty count, no note type list and no published set of supported capture languages. Without either list, coverage cannot be compared.